"Making Korea a DTx Hub"… The First 'DTx Asia' to Be Held

November 8-9 at Novotel Ambassador Gangnam, Seoul
World's Largest DTx Event 'DTx East' Sister Event
First Held in Seoul... Will It Become a Stepping Stone Toward a DTx Hub?

[Asia Economy Reporter Chunhee Lee] As the digital therapeutics (DTx) industry continues to grow rapidly, with the first approved digital therapeutic expected to be released domestically within this year, an event assessing the current status and future of the DTx industry in the Asia region is set to take place. Notably, the fact that the first event in the Asia region will be held in Seoul raises expectations that Korea will establish itself as a hub for the DTx industry.

According to industry sources on the 4th, the "1st DTx Asia" will be held over two days, from the 8th to the 9th, at the Novotel Ambassador in Gangnam-gu, Seoul. DTx Asia is the Asian sister event of "DTx East," the world's largest DTx event held annually mainly on the U.S. East Coast, and this year it will be held for the first time in Seoul. Additionally, "DTx West," centered on the U.S. West Coast, and "DTx Europe" are held annually.

DTx Asia has set the theme as "Establishing Digital Therapeutics in the APAC Markets." Originally, the first DTx Asia was scheduled to be held in Singapore, but the venue was later changed to Seoul. This is expected to be an opportunity for Korea to position itself as the hub of the continuously growing DTx industry in Asia.

The chairs of this event are Kim Jooyoung, co-chair of the Asia-Pacific Working Group of the Digital Therapeutics Alliance (DTA) and head of Welt's U.S. branch, and Abhishek Shah, CEO of Welsh Therapeutics.

On the first day’s keynote discussion, leaders in the global DTx field, including Chair Kim Jooyoung, CEO Abhishek Shah, Megan Coder, Vice President of Policy at DTA, and Sarah Jackson, Director at Click Therapeutics, will gather to discuss the expansion of DTx in Asia. Following this, Christopher Wasden, Chief Strategy Officer (CSO) of Twill, Louis Payet, Head of Mergers & Acquisitions at Zulik Pharma, Arbinder Singal, CEO of Peterfly, and Chen Kaishen, CEO of Sinocore, will continue discussions on the current state of DTx.

In addition, key figures related to domestic and international DTx, digital healthcare, and open innovation are expected to come together. Domestic presenters include Kang Sungji, CEO of Welt; Yoon Chan, CEO of EverX; Lee Jungkyu, CEO of Bridge Biotherapeutics; Park Jaemin, CEO of Tyroscope; Lee Jongmyung, CEO of Skia; and Hwang Kyungmin, CEO of Vpix, who will present in various sessions. Regarding investment, Lee Haesung, head of KT Digital Health P-TF; Kwon Sohyun, CEO of InnoCube; and Choi Yunseop, CEO of Digital Healthcare Partners (DHP), will participate. Academia and government will also present, including Professor Kim Daejin of Catholic University Seoul St. Mary’s Hospital (CEO of Digital Pharm) and Han Youngmin, officer of the Digital Health Regulatory Support Division at the Ministry of Food and Drug Safety.

From overseas, key speakers include Siva Nadarajah, co-founder of Jogo Health; Kamal Jethwani, CEO of Decimal Health; Tanigawa Tomoyuki, Chief Medical Officer (CMO) of CureApp; and Sharon Chan, head of JLABS Asia Pacific at Johnson & Johnson (J&J).